Keresés eredménye

Típusa:

összetett keresés

Keresési paraméterek:

Jon Ukropec, PhD | szakcikk |

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

859 Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Szerző: Maria-Victoria Mateos¹ Michele Cavo² Joan Bladé, MD, PhD³ Meletios A. Dimopoulos, MD⁴ Kenshi Suzuki, MD, PhD⁵ Andrzej Jakubowiak, MD, PhD⁶ Stefan Knop⁷ Chantal Doyen, MD⁸ Paulo Lucio, MD, PhD⁹ Zsolt Nagy, MD, PhD¹⁰ Ludek Pour, MD¹¹ Mark Cook, MBChB, PhD¹² Sebastian Grosicki, MD, PhD¹³ Andre H Crepaldi, MD¹⁴ Anna Marina Liberati¹⁵ Philip Campbell, MBBS, FRACP, FRCPA¹⁶ Tatiana Shelekhova¹⁷ Sung-Soo Yoon, MD, PhD¹⁸ Genadi Iosava, MD¹⁹ Tomoaki Fujisaki, MD, PhD²⁰ Mamta Garg, MD, FRCP, FRCPath²¹ Maria Krevvata, PhD²² Jianping Wang²³ Anupa Kudva, MD²⁴ Jon Ukropec, PhD²⁵ Susan Wroblewski, PhD²⁶ Rachel Kobos, MD²⁷ Jesus San-Miguel, MD, PhD²⁸
¹University Hospital of Salamanca/IBSAL, Salamanca, Spain
²Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
³Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
⁴National and Kapodistrian University of Athens, Athens, Greece
⁵Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
⁶University of Chicago Medical Center, Chicago, IL
⁷Würzburg University Medical Center, Würzburg, Germany
⁸Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
⁹Champalimaud Centre for the Unknown, Lisbon, Portugal
¹⁰Semmelweis Egyetem, Budapest, Hungary
¹¹University Hospital Brno, Brno, Czech Republic
¹²University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom
¹³Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
¹⁴Clinica de Tratamento E, Cuiaba, Brazil
¹⁵Azienda Ospedaliera "Santa Maria", Terni, Italy
¹⁶Andrew Love Cancer Centre, Geelong, Australia
¹⁷Clinic of Professional Pathology, Saratov, RUS
¹⁸Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
¹⁹LTD “Medinvent” Institute of Health, Tbilisi, Georgia
²⁰Matsuyama Red Cross Hospital, Matsuyama, Japan
²¹Leicester Royal Infirmary, Leicester, United Kingdom
²²Janssen Research & Development, LLC, Spring House, PA
²³Janssen Research & Development, LLC, Raritan, NJ
²⁴Janssen Research & Development, LLC, Raritan, NJ
²⁵Janssen Global Medical Affairs, Horsham, PA
²⁶Janssen Research & Development, LLC, Spring House, PA
²⁷Janssen Research & Development, LLC, Raritan, NJ
²⁸Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

Conclusions: For the first time, we demonstrate that the addition of DARA to VMP prolongs OS in patients with transplant-ineligible NDMM, with a 40% reduction in the risk of death versus VMP alone after a median follow-up of 40 months. D-VMP continued to demonstrate a significant PFS benefit, which was also maintained during the subsequent line of therapy. These findings, together with the phase 3 MAIA study (DARA plus lenalidomide/dexamethasone ...

1875 Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of MaiaClinically Relevant Abstract

Szerző: Nizar Bahlis, MD¹ Thierry Facon, MD² Saad Z. Usmani, MD³ Shaji K. Kumar, MD⁴ Torben Plesner, MD, DSc⁵ Robert Z. Orlowski, MD, PhD⁶ Cyrille Touzeau, MD⁷ Supratik Basu, MBBS, MD, FRCP, FRCPath⁸ Hareth Nahi, MD, PhD⁹ Cyrille Hulin, MD¹⁰ Hang Quach, MD¹¹ Hartmut Goldschmidt¹² Michael E O'Dwyer, MD¹³ Christopher P Venner, MD¹⁴ Katja C. Weisel, MD¹⁵ Maria Krevvata, PhD¹⁶ Huiling Pei, PhD¹⁷ Jianping Wang¹⁸ Rian Van Rampelbergh¹⁹ Jon Ukropec, PhD²⁰ Clarissa M. Uhlar²¹ Rachel Kobos, MD²² Aurore Perrot²³
¹University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
²Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
³Levine Cancer Institute/Atrium Health, Charlotte, NC
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁶Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Hematology, University Hospital Hôtel-Dieu, Nantes, France
⁸Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom
⁹Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
¹⁰Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
¹¹St. Vincent's Hospital, Melbourne, Australia
¹²University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg, Germany
¹³Dept. of Medicine/Haematology, NUI, Galway, Ireland
¹⁴Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada
¹⁵Medical Center of Hamburg-Eppendorf, Hamburg, Germany; University of Tuebingen, Tuebingen, Germany
¹⁶Janssen Research & Development, LLC, Spring House, PA
¹⁷Janssen Research & Development, LLC, Titusville, NJ
¹⁸Janssen Research & Development, LLC, Raritan, NJ
¹⁹Janssen Research & Development, Beerse, Belgium
²⁰Janssen Global Medical Affairs, Horsham, PA
²¹Janssen Research & Development, LLC, Spring House, PA
²²Janssen Research & Development, LLC, Raritan, NJ
²³Hematology Department, University Hospital, Vandoeuvre Les Nancy, France

Conclusion: After longer follow up, the addition of DARA to Rd continues to demonstrate a significant PFS benefit and improved rates of deeper and more durable responses vs Rd alone in patients with transplant-ineligible NDMM. The longer follow-up also demonstrated a significant improvement in PFS2 favoring D-Rd, and no new safety concerns were observed. These results continue to support the use of D-Rd in the first line of treatment for ...

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!